Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1] - The company will present its Gene Circuit technology, pipeline progress, and strategic priorities at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases by leveraging a synthetic biology platform to engineer Gene Circuits [3] - The Gene Circuits are designed to specifically target and kill cancer cells while sparing healthy cells, increasing specificity to target tissues, and allowing for control even after administration [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at addressing challenging liquid and solid tumor indications, with preclinical evidence supporting their efficacy in both NK and T cells [3] - Senti Bio is also exploring the potential applications of Gene Circuits in other modalities and diseases beyond oncology through ongoing partnerships [3]